Dec 21, 2023
Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease whose management is complex and requires open communication amongst a multidisciplinary care team. It has a high rate of relapse, with up to 40 percent of patients relapsing within the first two years after primary treatment. Management of a patient with...
Dec 14, 2023
As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer...